Get Premium to unlock powerful stock data
NAS:INDP (USA)   Healthcare » Biotechnology
Indaptus Therapeutics Inc logo

Indaptus Therapeutics Inc $ 7.81 0.27 (3.58%)

Volume:
695,666
Avg Vol (1m):
5,993,016
Market Cap $:
42.22 Mil
Enterprise Value $:
24.40 Mil
PE Ratio:
At Loss
PB Ratio:
3.04
Warning! GuruFocus has detected 2 Good signs with INDP. Click here to check it out.
EMBED
5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for INDP (Indaptus Therapeutics Inc) from 2021 to Oct 20 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Indaptus Therapeutics stock (INDP) PE ratio as of Oct 20 2021 is 0. More Details

Indaptus Therapeutics PE Ratio (TTM) Chart

EMBED

Indaptus Therapeutics PE Ratio (TTM) Historical Data

Total 0
  • 1
Indaptus Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data

Indaptus Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Indaptus Therapeutics Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 541714 SIC : 2834
Compare
Traded in other countries / regions
Address
Three Columbus Circle, 15th Floor, New York, NY, USA, 10019
Website
https://www.indaptusrx.com
Indaptus Therapeutics Inc is positioned to revolutionize the treatment of cancer and certain infectious diseases. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.